InvestSMART

Osteopore Limited (ASX:OSX)

ALERT: Price-sensitive ASX Announcement for OSX
Current share price for OSX : $0.005 -0.005 (-50%)+
Announcement
Release
31 Oct 2025 9:29AM
Price at Release
$0.010
Full Release
download
Summary
Osteopore Limited's quarterly report for the period ending September 30, 2025, highlights a revenue growth of 7% year-on-year, with a total revenue of AUD 812K for Q3 CY25. The company secured EU MDR clearance for its implants in Switzerland and expanded its sales through a partnership with Zimmer Biomet, resulting in a threefold increase in implant sales in several regions. Osteopore also succeeded in winning tender bids in Vietnam. The report details net cash used in operating activities of AUD 664,000, with ongoing financing facilities and a current cash balance of AUD 1,081,000. Payments to related parties totaled AUD 199,000.
Key Points
  • Osteopore recorded a revenue of AUD 812K for Q3 CY25, marking a 7% year-on-year growth.
  • The company secured market approval in Switzerland under the EU MDR clearance for its orthopedic and cranial implants.
  • Osteopore's partnership with Zimmer Biomet led to a threefold increase in implant sales in Europe, the Middle East, Africa, and Asia Pacific.
  • Osteopore won tender bids for two major public hospitals in Vietnam for orthopedic products.
  • The company reported net cash used in operating activities of approximately A$664,000 for the quarter.
  • Osteopore maintains access to a redeemable convertible note facility with a nominal value of up to A$20,000,000, with A$4,000,000 drawn as of September 2025.
  • Payments to related parties during the quarter amounted to approximately A$199,000.
  • Osteopore has a cash balance of approximately A$1,081,000 at the end of the quarter.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.